❌

Normal view

Received — 4 April 2026 ⏭

Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer

✇(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
By: Xiaomeng Li · Xuejiao Li · Hongbo Wu · Rui Li
3 April 2026 at 18:00

Oncol Res. 2026 Mar 23;34(4):11. doi: 10.32604/or.2026.076176. eCollection 2026.

ABSTRACT

Lung cancer remains the leading cause of cancer-related mortality worldwide, primarily driven by metabolic reprogramming and immune evasion mechanisms within tumor cells. To adapt to the nutrient-deprived tumor microenvironment (TME), lung cancer cells undergo profound metabolic reprogramming, characterized by enhanced glycolysis (the Warburg effect), increased glutamine dependency (mediated by GLS1), and accelerated lipid synthesis (involving enzymes such as FASN). These metabolic alterations not only remodel the TME but also dampen antitumor immune responses by promoting immunosuppressive cell populations (e.g., Tregs and M2 macrophages) and inhibiting effector functions of CD8+ T cells and natural killer (NK) cells. Critically, a bidirectional crosstalk operates between tumor cell metabolism and the immunosuppressive TME: metabolic reprogramming drives immune suppression through metabolite accumulation, whereas the immunosuppressive TME, in turn, promotes tumor cell adaptability-thus forming a positive feedback loop that reinforces immune evasion and therapy resistance. This review elucidates key molecular pathways governing metabolic reprogramming in lung cancer-spanning glucose, amino acid, and lipid metabolism-and their dynamic crosstalk with immune regulation, including epigenetic modifications and non-coding RNA-mediated mechanisms. Additionally, it evaluates emerging therapeutic strategies targeting the metabolic-immune axis, such as inhibitors of HK2 or GLS1 combined with anti-PD-1/PD-L1 agents, which aim to reverse immunosuppression and improve clinical outcomes. By synthesizing recent advances, this work provides a theoretical framework for precision oncology interventions, highlighting the potential of metabolic immunotherapies and future directions integrating AI and multi-omics data to overcome resistance in lung cancer.

PMID:41930159 | PMC:PMC13040304 | DOI:10.32604/or.2026.076176

Advances in Metabolic Reprogramming and Immune Regulatory Mechanisms in Lung Cancer

✇Omics In Lung
By: Xiaomeng Li · Xuejiao Li · Hongbo Wu · Rui Li
3 April 2026 at 18:00

Oncol Res. 2026 Mar 23;34(4):11. doi: 10.32604/or.2026.076176. eCollection 2026.

ABSTRACT

Lung cancer remains the leading cause of cancer-related mortality worldwide, primarily driven by metabolic reprogramming and immune evasion mechanisms within tumor cells. To adapt to the nutrient-deprived tumor microenvironment (TME), lung cancer cells undergo profound metabolic reprogramming, characterized by enhanced glycolysis (the Warburg effect), increased glutamine dependency (mediated by GLS1), and accelerated lipid synthesis (involving enzymes such as FASN). These metabolic alterations not only remodel the TME but also dampen antitumor immune responses by promoting immunosuppressive cell populations (e.g., Tregs and M2 macrophages) and inhibiting effector functions of CD8+ T cells and natural killer (NK) cells. Critically, a bidirectional crosstalk operates between tumor cell metabolism and the immunosuppressive TME: metabolic reprogramming drives immune suppression through metabolite accumulation, whereas the immunosuppressive TME, in turn, promotes tumor cell adaptability-thus forming a positive feedback loop that reinforces immune evasion and therapy resistance. This review elucidates key molecular pathways governing metabolic reprogramming in lung cancer-spanning glucose, amino acid, and lipid metabolism-and their dynamic crosstalk with immune regulation, including epigenetic modifications and non-coding RNA-mediated mechanisms. Additionally, it evaluates emerging therapeutic strategies targeting the metabolic-immune axis, such as inhibitors of HK2 or GLS1 combined with anti-PD-1/PD-L1 agents, which aim to reverse immunosuppression and improve clinical outcomes. By synthesizing recent advances, this work provides a theoretical framework for precision oncology interventions, highlighting the potential of metabolic immunotherapies and future directions integrating AI and multi-omics data to overcome resistance in lung cancer.

PMID:41930159 | PMC:PMC13040304 | DOI:10.32604/or.2026.076176

CORAL: Towards Autonomous Multi-Agent Evolution for Open-Ended Discovery

✇cs.AI, q-bio.NC updates on arXiv.org
By: Ao Qu · Han Zheng · Zijian Zhou · Yihao Yan · Yihong Tang · Shao Yong Ong · Fenglu Hong · Kaichen Zhou · Chonghe Jiang · Minwei Kong · Jiacheng Zhu · Xuan Jiang · Sirui Li · Cathy Wu · Bryan Kian Hsiang Low · Jinhua Zhao · Paul Pu Liang
3 April 2026 at 12:00
arXiv:2604.01658v1 Announce Type: new Abstract: Large language model (LLM)-based evolution is a promising approach for open-ended discovery, where progress requires sustained search and knowledge accumulation. Existing methods still rely heavily on fixed heuristics and hard-coded exploration rules, which limit the autonomy of LLM agents. We present CORAL, the first framework for autonomous multi-agent evolution on open-ended problems. CORAL replaces rigid control with long-running agents that explore, reflect, and collaborate through shared persistent memory, asynchronous multi-agent execution, and heartbeat-based interventions. It also provides practical safeguards, including isolated workspaces, evaluator separation, resource management, and agent session and health management. Evaluated on diverse mathematical, algorithmic, and systems optimization tasks, CORAL sets new state-of-the-art results on 10 tasks, achieving 3-10 times higher improvement rates with far fewer evaluations than fixed evolutionary search baselines across tasks. On Anthropic's kernel engineering task, four co-evolving agents improve the best known score from 1363 to 1103 cycles. Mechanistic analyses further show how these gains arise from knowledge reuse and multi-agent exploration and communication. Together, these results suggest that greater agent autonomy and multi-agent evolution can substantially improve open-ended discovery. Code is available at https://github.com/Human-Agent-Society/CORAL.

ATBench: A Diverse and Realistic Trajectory Benchmark for Long-Horizon Agent Safety

✇cs.AI, q-bio.NC updates on arXiv.org
By: Yu Li · Haoyu Luo · Yuejin Xie · Yuqian Fu · Zhonghao Yang · Shuai Shao · Qihan Ren · Wanying Qu · Yanwei Fu · Yujiu Yang · Jing Shao · Xia Hu · Dongrui Liu
3 April 2026 at 12:00
arXiv:2604.02022v1 Announce Type: new Abstract: Evaluating the safety of LLM-based agents is increasingly important because risks in realistic deployments often emerge over multi-step interactions rather than isolated prompts or final responses. Existing trajectory-level benchmarks remain limited by insufficient interaction diversity, coarse observability of safety failures, and weak long-horizon realism. We introduce ATBench, a trajectory-level benchmark for structured, diverse, and realistic evaluation of agent safety. ATBench organizes agentic risk along three dimensions: risk source, failure mode, and real-world harm. Based on this taxonomy, we construct trajectories with heterogeneous tool pools and a long-context delayed-trigger protocol that captures realistic risk emergence across multiple stages. The benchmark contains 1,000 trajectories (503 safe and 497 unsafe), averaging 9.01 turns and 3.95k tokens, with 1,954 invoked tools drawn from pools spanning 2,084 available tools. Data quality is supported by rule-based and LLM-based filtering plus full human audit. Experiments on frontier LLMs, open-source models, and specialized guard systems show that ATBench is challenging even for strong evaluators, while enabling taxonomy-stratified analysis, cross-benchmark comparison, and diagnosis of long-horizon failure patterns.
There are no more articles
❌